Biomedical & Therapeutics
Novel Compounds to Fight Microbial Sepsis
A new class of compounds that can serve as a Lipid A-like LPS antagonist, with potential as a therapeutic agent for microbial sepsis.
University of Missouri–St. Louis
Technology overview
A new class of compounds that act as Lipid A-like lipopolysaccharide (LPS) antagonists, with potential as therapeutic agents for the treatment of microbial sepsis.
Commercial applications
Therapeutics for microbial sepsis; Lipid A / LPS antagonism.
Key advantages
A new class of Lipid A-like LPS antagonists with therapeutic potential for microbial sepsis.
Licensing
Connect with the technology transfer office to discuss terms.
Inquire about licensing Email directlyKeywords
sepsisLPS antagonistLipid Aanti-infectivetherapeutic